Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across Annovis’ Alzheimer’s disease and Parkinson’s disease programs, including translational science, clinical development, biomarker strategy and regulatory interactions.
The company said Fang’s promotion comes as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application submission. Annovis said Fang has played a key role in advancing the company’s clinical development efforts and will lead its scientific strategy through upcoming clinical and regulatory milestones. The full press release is available at https://ibn.fm/c9jdt.
Annovis Bio is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
This promotion signals Annovis’ strategic focus on advancing its pipeline through critical regulatory and clinical stages. With Fang at the helm of scientific strategy, the company is poised to navigate the complexities of late-stage drug development. The upcoming Phase 3 Alzheimer’s data will be pivotal for buntanetap’s potential approval, and Fang’s expertise in translational science and biomarker strategy will be instrumental in interpreting results and guiding regulatory interactions.
For more information on Annovis Bio, visit their website at https://www.annovisbio.com. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
This announcement underscores the importance of strong leadership in biotechnology companies approaching key milestones. As Annovis Bio prepares for data readouts and regulatory submissions, the appointment of a dedicated Chief Scientific Officer could enhance the company’s ability to successfully bring buntanetap to market, potentially offering new treatment options for patients with Alzheimer’s and Parkinson’s diseases.
